Blood pressure stability in a normotensive population during intake of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 g gestodene

European Journal of Contraception and Reproductive Health Care

Volumn 6, Issue 3, 2001, Pages 159-166

  Endrikat, J ^a   Gerlinger, C ^a   Cronin, M ^a   Ruebig, A ^a   Schmidt, W ^b   Dusterberg B ^a  

^a BAYER PHARMA AG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Blood pressure; Ethinylestradiol; Gestodene; Oral contraceptives

Indexed keywords

ETHINYLESTRADIOL; GESTODENE; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; BLOOD PRESSURE; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ETHINYL ESTRADIOL; FEMALE; HUMAN; NORPREGNENES; RETROSPECTIVE STUDIES;

EID: 0035459104     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/ejc.6.3.159.166     Document Type: Article

References (15)

1. Chalmer J for the 1999 WHO-International Society of Hypertension/Mild Hypertension Guidelines Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17: 151-83
2. Brownrigg, GM. Toxaemia in hormone-induced pseudo-pregnancy. Can Med Assoc J 1962;87:408-9
3. Kunin CM, McCormack, Abernathy JR. Oral contraceptives and blood pressure. Arch Intern Med 1969;123: 363-5
4. Royal College of General Practitioners. Hypertension. In Oral Contraceptives and Health. London: Pitman, 1974:37-42
5. Düsterberg B, Ellman H, Müller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996; 10:33-9
6. Endrikat J, Düsterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel in a multi-center clinical study. Contraception 1999;60:269-74
7. Fuchs N, Düsterberg B, Weber-Diehl F, et al The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene. Contraception 1995;51:33-9
8. Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993;47:367-76
9. Godsland I, Crook D, Devenport M, et al. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception 1995;52:143-9
10. Archer D, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinylestradiol 20 μg. Contraception 1997;55:139-44
11. Poulter N. Oral contraceptives and blood pressure. In Hannsford PC, Webb A, eds. Evidence-guided Prescribing of the Pill. Carnforth, UK: Parthenon Publishing, 1996:77-88
12. Oelkers W, Schoneshofer M, Blumel A. The effects of progesterone and four synthetic progestogens on sodium balance and the renin-aldosterene system in man. J Clin Endocrinol Metab 1974;39:882-90
13. Elstein M, Furniss H. Advances in oral hormonal contraception. Zentralbl Gynecol 1995;117:559-65
14. Prentice R. On the ability of blood pressure effects to explain the relation between oral contraceptives and cardiovascular disease. Am J Epidemiol 1988;127:213-19
15. Endrikat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/ 75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, with respect to efficacy, cycle control and tolerance. Contraception 1997;55:131-7